Keyword Search
 

2018 | 2017 | 2016 | 2015 | 2014
Ocular Therapeutix™ to Present at Oppenheimer 25th Annual Healthcare Conference

Ocular Therapeutix™ Reports Third Quarter 2014 Financial Results

Ocular Therapeutix™ Enrolls First Patients in Phase 2b Clinical Trial for Sustained Release Travoprost for the Treatment of Glaucoma and Ocular Hypertension

Ocular Therapeutix™ Announces Top-Line Results from Phase 2 Sustained Release Dexamethasone Trial for Allergic Conjunctivitis

Ocular Therapeutix™ to Report Third Quarter 2014 Financial Results and Provide Business Updates on Wednesday, November 12, 2014

Ocular Therapeutix™ to Participate in Two Investor Conferences in November 2014

Ocular Therapeutix™ to Attend American Academy of Ophthalmology Annual Meeting in Chicago, Illinois

Ocular Therapeutix™ Completes Enrollment in Phase 3 Sustained Release Dexamethasone Trials for Post-Operative Inflammation and Pain

Ocular Therapeutix to Present at the 21st Annual NewsMakers in the Biotech Industry Investment Conference on Friday, September 26

Ocular Therapeutix to Present at Morgan Stanley 2014 Global Healthcare Conference

Ocular Therapeutix Announces Second Quarter 2014 Financial Results

Ocular Therapeutix Announces Exercise of Over-Allotment Option

Ocular Therapeutix Announces Closing of Initial Public Offering

Ocular Therapeutix Prices Initial Public Offering

Ocular Therapeutix to Present New Data on Sustained Release Drug Candidates Utilizing Proprietary Hydrogel Technology at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Novel Hydrogel Sealant and Sustained Release Drug Technology Data to be Presented at the ASCRS Annual Symposium

Ocular Therapeutix Begins Phase 3 Clinical Trial for its Sustained Release Dexamethasone

Ocular Therapeutix Secures Reimbursement Code for Insertion of Drug-eluting Intracanalicular Plugs

Duke University Eye Center Performs First Cataract Surgeries using the ReSure® Sealant

Ocular Therapeutix receives FDA approval for the ReSure® Sealant